{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T13:10:43Z","timestamp":1774703443353,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T00:00:00Z","timestamp":1546041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201809350002"],"award-info":[{"award-number":["201809350002"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.psychres.2018.12.159","type":"journal-article","created":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T17:24:05Z","timestamp":1546104245000},"page":"643-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["High serum levels of FGF21 are decreased in bipolar mania patients during psychotropic medication treatment and are associated with increased metabolism disturbance"],"prefix":"10.1016","volume":"272","author":[{"given":"Qing","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psychres.2018.12.159_bib0001","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000067809","article-title":"Serum leptin and cholesterol levels in patients with bipolar disorder","volume":"46","author":"Atmaca","year":"2002","journal-title":"Neuropsychobiology"},{"issue":"2","key":"10.1016\/j.psychres.2018.12.159_bib0002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0165-1781(96)02909-5","article-title":"Sleep loss, a possible factor in augmenting manic episode","volume":"65","author":"Barbini","year":"1996","journal-title":"Psychiatry Res."},{"issue":"10","key":"10.1016\/j.psychres.2018.12.159_bib0003","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.mayocp.2017.06.022","article-title":"The diagnosis and management of bipolar I and II disorders: clinical practice update","volume":"92","author":"Bobo","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"9","key":"10.1016\/j.psychres.2018.12.159_bib0004","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.3249","article-title":". FGF21 regulates metabolism and circadian behavior by acting on the nervous system","volume":"19","author":"Bookout","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.psychres.2018.12.159_bib0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/07853890.2012.687835","article-title":"The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders","volume":"45","author":"Calkin","year":"2013","journal-title":"Ann. Med."},{"issue":"4","key":"10.1016\/j.psychres.2018.12.159_bib0006","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/ijnp\/pyx093","article-title":"FGF21 is associated with metabolic effects and treatment response in depressed bipolar II disorder patients treated with valproate","volume":"21","author":"Chang","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.psychres.2018.12.159_bib0007","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1210\/jc.2008-0746","article-title":". Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa","volume":"93","author":"Dostalova","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"43","key":"10.1016\/j.psychres.2018.12.159_bib0008","doi-asserted-by":"crossref","first-page":"15506","DOI":"10.1073\/pnas.0406788101","article-title":". Dysregulation of the fibroblast growth factor system in major depression","volume":"101","author":"Evans","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"2","key":"10.1016\/j.psychres.2018.12.159_bib0009","first-page":"180","article-title":"Metabolic syndrome and psychotropic medications","volume":"9","author":"Filakovic","year":"2012","journal-title":"Med. Glas. (Zenica)"},{"issue":"9878","key":"10.1016\/j.psychres.2018.12.159_bib0010","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","article-title":"Treatment of bipolar disorder","volume":"381","author":"Geddes","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.psychres.2018.12.159_bib0011","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1034\/j.1399-5618.2000.020109.x","article-title":"Cholesterol levels in mood disorders: high or low?","volume":"2","author":"Ghaemi","year":"2000","journal-title":"Bipolar Disord."},{"issue":"Pt 1","key":"10.1016\/j.psychres.2018.12.159_bib0012","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mce.2015.09.018","article-title":"Fibroblast growth factor-21, energy balance and obesity","volume":"418","author":"Giralt","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"issue":"3","key":"10.1016\/j.psychres.2018.12.159_bib0013","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bdi.12035","article-title":"Obesity and the three-year longitudinal course of bipolar disorder","volume":"15","author":"Goldstein","year":"2013","journal-title":"Bipolar Disord."},{"issue":"10027","key":"10.1016\/j.psychres.2018.12.159_bib0014","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.psychres.2018.12.159_bib0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0165-1781(03)00186-0","article-title":"Increased levels of serum basic fibroblast growth factor in schizophrenia","volume":"120","author":"Hashimoto","year":"2003","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2018.12.159_bib0016","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neulet.2014.07.035","article-title":"Decreased serum fibroblast growth factor - 2 levels in pre- and post-treatment patients with major depressive disorder","volume":"579","author":"He","year":"2014","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.psychres.2018.12.159_bib0017","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.genhosppsych.2015.04.003","article-title":"Increased risk of hyperlipidemia in patients with bipolar disorder: a population-based study","volume":"37","author":"Hsu","year":"2015","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.psychres.2018.12.159_bib0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fendo.2014.00107","article-title":"FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases","volume":"5","author":"Itoh","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.psychres.2018.12.159_bib0019","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fendo.2015.00154","article-title":"Endocrine FGFs: evolution, pphysiology, pathophysiology, and pharmacotherapy","volume":"6","author":"Itoh","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.psychres.2018.12.159_bib0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.molmet.2013.12.003","article-title":"Inventing new medicines: the FGF21 story","volume":"3","author":"Kharitonenkov","year":"2014","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.psychres.2018.12.159_bib0021","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/mp.2013.192","article-title":". FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers","volume":"20","author":"Leng","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.psychres.2018.12.159_bib0022","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2193-1801-3-2","article-title":". Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1alpha in human dopaminergic neurons via Sirtuin-1","volume":"3","author":"Makela","year":"2014","journal-title":"Springerplus"},{"issue":"3","key":"10.1016\/j.psychres.2018.12.159_bib0023","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":". Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2018.12.159_bib0024","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1755-5949.2011.00232.x","article-title":"Obesity and psychotropics","volume":"18","author":"Nihalani","year":"2012","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.psychres.2018.12.159_bib0025","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.psychres.2018.12.159_bib0026","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1176\/ajp.2006.163.10.1821","article-title":"Hyperlipidemia following treatment with antipsychotic medications","volume":"163","author":"Olfson","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2018.12.159_bib0027","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"issue":"9","key":"10.1016\/j.psychres.2018.12.159_bib0028","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/0004867415575380","article-title":"Increased serum fibroblast growth factor 21 levels in patients with schizophrenia","volume":"49","author":"Qing","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2018.12.159_bib0029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11011-015-9789-3","article-title":"Potential roles of fibroblast growth factor 21 in the brain","volume":"31","author":"Sa-Nguanmoo","year":"2016","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.psychres.2018.12.159_bib0030","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.pbb.2015.03.020","article-title":". Fibroblast growth factor 21 protects mouse brain against d-galactose induced aging via suppression of oxidative stress response and advanced glycation end products formation","volume":"133","author":"Yu","year":"2015","journal-title":"Pharmacol. Biochem. Behav."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178118315014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178118315014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T01:39:13Z","timestamp":1565228353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178118315014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":30,"alternative-id":["S0165178118315014"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2018.12.159","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High serum levels of FGF21 are decreased in bipolar mania patients during psychotropic medication treatment and are associated with increased metabolism disturbance","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2018.12.159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}